Staying Current with Approved and Emerging Evaluation and Treatment Regimens

CME

Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens
Credits Available

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: July 29, 2022

Expiration: July 29, 2023

Pretest

Progress
1 2
Course Completed
1.

How confident are you in your ability to treat your patients with metastatic pancreatic cancer?

2.

Your patient is a 69-year-old female with no family history of cancer. She presented with abdominal pain and weight loss. The workup revealed metastatic pancreatic cancer with diffuse liver and peritoneal metastases. She started first-line therapy with mFOLFIRINOX, which she tolerated reasonably well. Her disease burden improved after 4 cycles and again after 8 cycles. Somatic and germline tumor testing found KRAS and TP53 mutations only.

Which of the following treatment options would most closely match current guideline recommendations?

3.

Your patient is a 66-year-old female who presented with dyspepsia and weight loss. Workup revealed metastatic pancreatic cancer with diffuse liver metastases. She was initially treated with FOLFIRINOX but progresses after 6 months. Her performance status is 1.

What step would you most likely take next in this patient’s treatment?

4.

You elect to perform broad biomarker testing, including tests for NTRK fusions, BRCA1/2 mutations, and microsatellite instabilities. The patient’s test comes back positive for NTRK fusions. Which of the following treatments would you offer this patient?

5.

For a patient with a positive biomarker test for KRASG12C who wishes to avoid chemotherapy, which of the following might you recommend?

6.

Which of the following was observed in patients receiving nivolumab in a phase II trial of nivolumab in combination with gemcitabine and nab-paclitaxel?